Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DESONIDE

All products: not a benefit

Other products in the same Health Canada class (D07A, D07AB) — coverage varies; not interchangeable

  • Triamcinolone acetonide (Kenalog): general benefit, Not a benefit
  • Amcinonide (Cyclocort): general benefit, Not a benefit
  • Beclomethasone dipropionate (Propaderm): general benefit
  • Betamethasone dipropionate (Diprosone): general benefit
  • Betamethasone dipropionate in a base containing propylene glycol (Diprolene): general benefit
  • Betamethasone dipropionate in propylene glycol base (Diprolene Glycol): general benefit

8 more in the class list below

Tridesilon · DIN 02154870 · 0.05% · Oint

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2023-09-29 — choose a marketed DIN from the same-category list.Discontinued 2023-09-29 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2023-09-29 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2023-09-29 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Tridesilon · DIN 02154870 Manufacturer: Clay-Park Labs Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2023-09-29 · brand TRIDESILON 0.05% DESONIDE OINTMENT · ATC D07AB08 DESONIDE · form Ointment · route Topical · ingredients DESONIDE 0.05 % · company Perrigo international · schedule Prescription
Check this DIN again · Health Canada product record

Tridesilon: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=33931 · Verify on the e-Formulary ↗ (DIN 02154870)

Source record
DIN 02154870: Tridesilon Raw flags: notABenefit=Y, sec3=Y Item: 840600045; group id 842; item number 2052; lccId None; manufacturer id CPL Source form: Oint; strength: 0.05% Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02154870 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=33931
Interchangeable products
PDP-Desonide · DIN 02229323 · $0.2853
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02154870
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2023-09-29 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (84:06 Anti-Inflammatory) and how they are covered

Matched class: 84:06 Anti-Inflammatory

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL, BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE, CALCIPOTRIOL & BETAMETHASONE DIPROPIONATE, HALOBETASOL PROPIONATE, MOMETASONE FUROATE Some products covered without a code (check the product listing): AMCINONIDE, BETAMETHASONE DIPROPIONATE, BETAMETHASONE VALERATE, CLOBETASOL PROPIONATE, FLUOCINONIDE, HYDROCORTISONE, HYDROCORTISONE ACETATE, HYDROCORTISONE VALERATE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE 0.1% IN ORABASE 84:06 Anti-Inflammatory

TRIAMCINOLONE ACETONIDE

· 5 products · Listed, not a benefit (3), General benefit (2) · strengths: 0.1% · Cr, Oint

AMCINONIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 0.1% · Cr

BECLOMETHASONE DIPROPIONATE

· 2 products · General benefit · strengths: 0.025% · Cr, Oint

BETAMETHASONE DIPROPIONATE

· 6 products · General benefit (5), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 0.05% · Cr, Lot, Oint

BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL

· 2 products · General benefit · strengths: 0.05% · Oint

BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE

· 2 products · General benefit · strengths: 0.05% · Cr

BETAMETHASONE VALERATE

· 19 products · Listed, not a benefit (7), General benefit (12) · strengths: 0.05%, 0.1% · Cr, Lot, Oint, Scalp Lot

CLOBETASOL PROPIONATE

· 20 products · General benefit (11), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 0.05%, 0.05% w/w · Cr, Oint, Scalp Lot, Top Shampoo, Top Sol Sp

FLUOCINONIDE

· 8 products · General benefit (4), Listed, not a benefit (4) · strengths: 0.05% · Cr, Emol Cr, Gel, Oint

HALOBETASOL PROPIONATE

· 1 products · General benefit · strengths: 0.01% w/w · Lot

HYDROCORTISONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 0.5%, 1% · Oint

HYDROCORTISONE ACETATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 1% · Cr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:06 and 5 more
Full class listing Related classes: 84:04 Anti-Infectives, 84:28 Keratolytic Agents, 84:36 Miscellaneous Skin and Mucous Membrane Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE pdp-DESONIDE (desonide) 0.05% topical preparations are intended for use in the management of acute or chronic dermatoses. They have been demonstrated to have anti-inflammatory activity when used topically in:  Atopic Dermatitis  Contact Dermatitis (including Poison Ivy and Venenata)  Psoriasis  Eczema (including Nummular Eczema)  Neurodermatitis  Seborrheic Dermatitis  Lichen Simplex Chronicus (Lichen Planus)  Dyshidrosis  Acute Solar Dermatitis (Sunburn)  Statis Dermatitis 3 https://pdf.hres.ca/dpd_pm/00060564.PDF PM date: March 26, 2021 Source product: PDP-DESONIDE; DIN 02229315; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Tridesilon: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026